Lundbeck

37.26

DKK

-3.12 %

Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Market cap

37.1B DKK

Turnover

17.79M DKK

Revenue

22B

EBIT %

14.86 %

P/E

11.75

Dividend yield-%

2.55 %

Financial calendar

20/8

2025

Interim report Q2'25

12/11

2025

Interim report Q3'25

All

Press releases

ShowingAll content types

Regulatory press release5/22/2025, 3:31 PM

H. Lundbeck A/S: Lundbeck successfully places a EUR 500 million Eurobond

Regulatory press release5/14/2025, 5:17 AM

H. Lundbeck A/S: Lundbeck raises financial guidance following strong start to the year with strategic brands growth of +24% CER

Press release5/8/2025, 6:00 AM

H. Lundbeck A/S: Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release5/6/2025, 6:00 AM

H. Lundbeck A/S: Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer

Press release4/4/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Press release3/31/2025, 9:00 AM

H. Lundbeck A/S: Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Regulatory press release3/26/2025, 11:28 AM

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office

Press release3/13/2025, 8:00 AM

H. Lundbeck A/S: Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older

Press release3/10/2025, 8:01 AM

H. Lundbeck A/S: Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Regulatory press release2/25/2025, 9:00 AM

To the shareholders of H. Lundbeck A/S

Regulatory press release2/21/2025, 12:27 PM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Press release2/12/2025, 8:00 AM

H. Lundbeck A/S: Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA

Regulatory press release2/5/2025, 3:40 PM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/5/2025, 6:46 AM

H. Lundbeck A/S: Lundbeck Annual Report 2024

Regulatory press release2/5/2025, 6:23 AM

H. Lundbeck A/S: Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)

Regulatory press release2/4/2025, 4:10 PM

H. Lundbeck A/S: Lundbeck announces changes to the Board of Directors

Press release1/30/2025, 8:00 AM

H. Lundbeck A/S: Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies

Regulatory press release1/9/2025, 1:07 PM

H. Lundbeck A/S: Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD

Press release12/5/2024, 12:00 PM

H. Lundbeck A/S: Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Press release12/3/2024, 7:00 AM

H. Lundbeck A/S: Efficacy of Vyepti highlighted by new clinical trial results in severe migraine

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.